{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458273717
| IUPAC_name = Human Beta-glucocerebrosidase
| image =  
<!-- Clinical data -->
| tradename =  
| Drugs.com = {{drugs.com|monograph|imiglucerase}}
| MedlinePlus = a601149
| licence_EU = Cerezyme
| licence_US = Imiglucerase
| pregnancy_category =  
| legal_status =  
| routes_of_administration = Intravenous
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life = 3.6-10.4 min
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|CAS}}
| CAS_number = 154248-97-2
| ATC_prefix = A16
| ATC_suffix = AB02
| ATC_supplemental =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00053
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Q6U6J48BWY
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02810
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201632
<!-- Chemical data -->
| C=2532 | H=3854 | N=672 | O=711 | S=16
| molecular_weight = 55597.4 g/mol (un[[glycosylate]]d)
}}
'''Imiglucerase''' is a medication used in the treatment of [[Gaucher's disease]].<ref name="pmid18627336">{{cite journal |author=Weinreb NJ |title=Imiglucerase and its use for the treatment of Gaucher's disease |journal=Expert Opin Pharmacother |volume=9 |issue=11 |pages=1987–2000 |date=August 2008 |pmid=18627336 |doi=10.1517/14656566.9.11.1987 |url=http://www.expertopin.com/doi/abs/10.1517/14656566.9.11.1987}}</ref><ref name="pmid17079176">{{cite journal |vauthors=Starzyk K, Richards S, Yee J, Smith SE, Kingma W |title=The long-term international safety experience of imiglucerase therapy for Gaucher disease |journal=Mol. Genet. Metab. |volume=90 |issue=2 |pages=157–63 |date=February 2007 |pmid=17079176 |doi=10.1016/j.ymgme.2006.09.003 |url=http://linkinghub.elsevier.com/retrieve/pii/S1096-7192(06)00297-6}}</ref>

It is a [[recombinant DNA]]-produced [[Analog (chemistry)|analogue]] of human β-[[glucocerebrosidase]].
'''Cerezyme''' is a [[freeze-dried]] medicine containing imiglucerase, manufactured by [[Genzyme Corporation]]. It is given
[[intravenously]] after reconstitution as a treatment for Type 1 [[Gaucher's disease]].  It is available in formulations containing 200 or 400 units per vial.  The specific activity of highly purified human enzyme is 890,000 units/mg.<ref>{{cite journal|doi=10.1073/pnas.75.8.3970|journal=Proc. Natl. Acad. Sci. USA|volume=75|issue=8|pages=3970–3973|date=August 1978|title=Gaucher disease: Isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue|first5=SH|last5=Sorrell|first4=DE|last4=Britton|first3=HE|last3=Blair|first2=RO|last2=Brady|author=Pentchev|pmid=29293|pmc=392911|display-authors=etal}}</ref> A typical dose is 2.5U/kg every two weeks, up to a maximum of 60 U/kg once every two weeks, and safety has been established from ages 2 and up.<ref>{{cite web|url=http://www.cerezyme.com/global/pi.pdf|title=Cerezyme (imiglucerase for injection) Genzyme product data sheet}}</ref>  It is one of the most expensive drugs sold, with an annual cost to U.S. patients of $200,000.<ref name="Engelberg">{{cite journal | title =Perspective: Balancing Innovation, Access, and Profits — Market Exclusivity for Biologics | journal =N Engl J Med  | date =November 12, 2009 | authors =Alfred B. Engelberg, Aaron S. Kesselheim, and Jerry Avorn | volume =361 | issue =20 | pages =1917-1919 | url =http://www.nejm.org/doi/full/10.1056/NEJMp0908496 | doi =10.1056/NEJMp0908496 | pmid = | pmc = }}</ref> Imiglucerase has been granted [[orphan drug]] status in the United States, Australia, and Japan.<ref>{{cite web|url=http://www.orpha.net/consor/cgi-bin/Drugs_Search.php?lng=EN&data_id=23&Substance=Imiglucerase&search=Drugs_Search_SubstanceTradename&data_type=Product&diseaseType=Drug&Typ=Sub&title=&diseaseGroup=|title=Imiglucerase on Orpha.net: The portal for rare diseases and orphan drugs.}}</ref>

Cerezyme was one of the drugs manufactured at [[Genzyme|Genzyme's]] Allston, Massachusetts plant, for which production was disrupted in 2009 after contamination with Vesivirus 2117.<ref>{{cite journal|url=http://www.boston.com/business/healthcare/articles/2009/06/17/genzyme_temporarily_halts_production_on_2_key_drugs/|title=Virus shuts Genzyme plant, holds up drugs for 8,000|journal=The Boston Globe|author1=Erin Ailworth |author2=Robert Weisman |date=June 17, 2009}}</ref>

==See also==
*Other drugs for the treatment of Gaucher's disease
**[[Afegostat]] (development terminated)
**[[Eliglustat]]
**[[Miglustat]]
**[[Velaglucerase alfa]]
**[[taliglucerase alfa]]

==References==
{{reflist}}

{{Other alimentary tract and metabolism products}}

[[Category:Drugs acting on the gastrointestinal system and metabolism]]
[[Category:Orphan drugs]]
[[Category:Recombinant proteins]]


{{gastrointestinal-drug-stub}}